GlaxoSmithKline's Arranon Clears FDA For Refractory Leukemia & Lymphoma
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves nelarabine for treatment of twice-refractory T-cell leukemia and lymphoma patients Oct. 28.
You may also be interested in...
GSK’s Arranon Response Rates Likely To Predict Clinical Benefit In Leukemia/Lymphoma
FDA’s Oncologic Drug Products Advisory Committee votes for accelerated approval of Arranon for relapsed T-cell leukemia and lymphoma.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products